INVESTIGATION OF POSSIBLE APPROACHES TO ANGIOGENESIS REGULATION IN VITRO WITH THE HELP OF RECOMBINANT FRAGMENTS OF ANGIOGENESIS INHIBITORS SUCH AS ENDOSTATIN, TUMSTATIN AND PEDF

Cover Page

Abstract


Neovascular diseases of visual organ such as age-related macular degeneration, retinopathy of prematurity, diabetic retinopathy, thrombosis of central retina vein and its branches, neovascular glaucoma, choroid and retina tumors have the leading positions in the list of ophtalmopatologies that result in blindness and incapacity. The variety of angiostatic medications of applied ophtalmology is scant. The aim of work was to study the possibile approaches to angiogenesis regulation in vitro with the help of recombinant fragments of natural inhibitors of angiogenesis such as endostatin, tumstatin and PEDF (pigment epithelial derived factor), and also their ability to be the base of potentially feasible and pharmacologically active substances. It is determined that endostatin, tumstatin and PEDF, as well as the comparison medication Bevacizumab in vitro have pro- or antiangiogenic influence. The direction of the biological effect depends on the cultivation conditions, peptide concentration in the cultural fluid and stage of angiogenesis.

 


S. L. Kuznetsov

Sechenov First Moscow State Medical University, Russian Federation

Author for correspondence.
Email: kuznetsov@ramn.ru

Russian Federation RAMS cor. member, Head of the Department of Innovative Development of Science Russian Academy of Medical Sciences Address: 109240, Moscow, Soljanka St., 14; tel.: 8(495) 698-56-31

V. G. Likhvantseva

Lomonosov Moscow State University, Russian Federation

Email: info@fbm.msu.ru

Russian Federation PhD, Professor, Department of Fundamental Medicine Lomonosov Moscow State University Address: 119192, Moscow Lomonosov Ave, 31/5; tel: (495) 932-88-14

E. V. Arutyunyan

Lomonosov Moscow State University, Russian Federation

Email: ev1012@ya.ru

Russian Federation Ophthalmologist, City Hospital in Yubileiny Address: 141090, Moscow region, Yubileiny, Lesnaya St., 8/10; tel.: 8(498)-646-96-80

K. A. Kuz'min

Lomonosov Moscow State University, Russian Federation

Email: info@fbm.msu.ru

Russian Federation Pathologist, Pathology Department of the Central Clinical Hospital Russian Academy of Sciences Address: 119333, Moscow, Litovskiy Blvd, 1A; tel.: (495) 921-34-74

S. A. Sel'kov

D.O. Ott Research Institute of Obstetrics and Gynecology, St. Petersburg, Russian Federation

Email: iagmail@ott.ru

Russian Federation PhD, Professor, Head of the Immunology Laboratory, Research Institute of Obstetrics and Gynecology named after D.O. Otta Address: 199034, St. Petersburg, Mendeleev line 3; tel.: (812) 328-14-02

D. I. Sokolov

D.O. Ott Research Institute of Obstetrics and Gynecology, St. Petersburg, Russian Federation

Email: iagmail@ott.ru

Russian Federation PhD, Head of the Group of Angiogenesis Study of Immunology Laboratory, Research Institute of Obstetrics and Gynecology named after D.O. Otta Address: 199034, St. Petersburg, Mendeleev line 3; tel.: (812) 328-14-02

  1. Zhukov N.V. The current state of antianioennoy therapy. Target therapy without a target? Prakt. onkol. = Practical oncology. 2007; 8 (3): 164–170.
  2. Ziangirova G.G., Likhvantseva V.G. Osobennosti i rol' aniogeneza v opukholyakh. V knige: Opukholi sosudistogo trakta glaza [Features and Angiogenesis Role in Tumors. In: Tumors of Vascular Tract of the Eye]. Moscow, Poslednee slovo, 2003. 456 p.
  3. Ellington A.D., Szostak J.W. In vitro selection of RNA molecules that bind specific ligands. Nature. 1990; 346: 818–822.
  4. Eyetech Study Group: Preclinical and phase IA clinical evalution of anti-VEGF pegylatedaptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina. 2002; 22: 143-152.
  5. Folkman J. Tumor angiogenesis: Cancer Medicine. J.F. Holland, R.C. Bast, D.L. Morton, E. Frei, D.W. Kufe, R.R. Weichselbaum (eds.). Baltimore: Williams&Wilkins. 1997. P. 181–204.
  6. Paccola L, Costa RA, Folgosa MS, Barbosa JC, Scott IU, Jorge R. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema IBEME study). Brit. J. Ophthalmology. 2008; 92: 76–80.
  7. Presta, L. G., Chen, H., O’Connor, S. J., Chisholm, V., Meng, Y. G., Krummen, L. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumor and other disorders. Cancer Res. 1997; 57: 4593–4599.
  8. Colella P., Corugno G., Auricchio A. Ocular gene therapy: current progress and future prospects. Trends in Molecular Medicine, 15 (1):, 2008; Р.23–31.
  9. Developments in Ophthalmology. Anti-VEGF. F. Bandello, M. BattagliaParodi (eds.). Karger–Basel. 2010. 144 p.
  10. Noel A., Lost M., Lambert V. Lecomte J., Marie Rakic J. Anti-angiogenic therapy of exudative ages macular degeneration:current progress and emerging concepts. Trends Mol. Med. 2007; 13 (8): 345–352.
  11. Lux A., Llacer H., Heussen F. et al. Non-responders to bevacizumab (Avastin) therapy of choroidalneovascular lesions. Brit. J. Ophthalmol. 2007; 91 (10): 1318–1322.
  12. Eghøj M.S., Sørensen T.L. Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Brit. J. Ophthalmol. 2011; 96: 21–23.
  13. Schaal S., Kaplan H.J., Tetzel T.H. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology. 2008; 115: 2199–2205.

Views

Abstract - 15

PDF (Russian) - 11

Cited-By


PlumX



Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies